Prenetics Global Limited (NASDAQ:PRE) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Prenetics Global Limited (NASDAQ:PRE) have received a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $34.25.

Several equities research analysts recently weighed in on PRE shares. Wall Street Zen downgraded Prenetics Global from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Benchmark boosted their price target on shares of Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a research report on Friday, July 17th.

Prenetics Global Stock Performance

NASDAQ PRE opened at $18.46 on Thursday. The firm’s fifty day moving average is $19.42 and its two-hundred day moving average is $18.81. Prenetics Global has a one year low of $7.18 and a one year high of $23.63. The firm has a market cap of $311.42 million, a PE ratio of -4.03 and a beta of 0.26.

Prenetics Global (NASDAQ:PRE) last released its quarterly earnings results on Wednesday, June 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.07). The company had revenue of $35.95 million for the quarter, compared to analysts’ expectations of $36.00 million. Prenetics Global had a negative return on equity of 20.33% and a negative net margin of 62.45%. Research analysts predict that Prenetics Global will post -1.28 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PRE. 683 Capital Management LLC purchased a new stake in shares of Prenetics Global during the 4th quarter worth $1,181,000. T3 Companies LLC acquired a new position in Prenetics Global during the fourth quarter worth about $170,000. Kingsview Wealth Management LLC purchased a new position in Prenetics Global in the fourth quarter valued at about $172,000. Stevens Capital Partners lifted its position in shares of Prenetics Global by 4.7% during the 4th quarter. Stevens Capital Partners now owns 18,207 shares of the company’s stock valued at $287,000 after acquiring an additional 825 shares during the period. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Prenetics Global during the 3rd quarter worth approximately $65,000. Hedge funds and other institutional investors own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.